SCHEMBL5788239

SCHEMBL5788239

Cc1cc(N2CCCC2)nc(C=Cc2cccc(O)c2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 2/20 0.56
LMNA P02545 2/20 0.47
APAF1 O14727 1/20 0.47
MAPT P10636 1/20 0.47
PPP1CA P62136 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 3/20 0.47
HPGD P15428 2/20 0.47
HSD17B10 Q99714 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
USP2 O75604 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
NR1I2 O75469 1/20 0.46
PGR P06401 1/20 0.46
ADORA3 P0DMS8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5788232 1.00 PDE10A (0.56) PDE10ALMNAAPAF1MAPTPPP1CA
SCHEMBL5788393 0.85 PDE10A (0.54) PDE10AMAPTCYP1A2
SCHEMBL5788397 0.85 PDE10A (0.54) PDE10AMAPTCYP1A2
SCHEMBL5789535 0.85 PDE10A (0.56) PDE10ALMNAMAPTALDH1A1KDM4E
SCHEMBL5790622 0.85 PDE10A (0.56) PDE10ALMNAMAPTALDH1A1KDM4E
SCHEMBL5790613 0.85 PDE10A (0.56) PDE10ALMNAMAPTALDH1A1KDM4E
SCHEMBL5786942 0.85 PDE10A (0.56) PDE10ALMNAMAPTALDH1A1KDM4E
SCHEMBL5789538 0.85 PDE10A (0.56) PDE10ALMNAMAPTALDH1A1KDM4E
SCHEMBL5787760 0.85 PDE10A (0.56) PDE10ALMNAMAPTALDH1A1KDM4E
SCHEMBL5788378 0.84 PDE10A (0.53) PDE10ALMNAALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6657060-B2 Neuropeptide Y antagonists; treatment of eating disorders such as obesity and hyperphagia HOFFMAN-LA ROCHE INC. 2003-12-02 US claimed
US-20020086858-A1 Pyrimidine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2002-07-04 US claimed
EP-1335906-B1 PYRIMIDINE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2006-09-27 EP disclosed
US-6657060-B2 Neuropeptide Y antagonists; treatment of eating disorders such as obesity and hyperphagia HOFFMAN-LA ROCHE INC. 2003-12-02 US disclosed
US-20020086858-A1 Pyrimidine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2002-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086858-A1 Pyrimidine derivatives NPY1R, NPY5R, NPY4R PDE10A 2005/4885LMNA 4277/4885APAF1 1241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.